{
    "clinical_study": {
        "@rank": "116043", 
        "acronym": "ADDRESS II", 
        "arm_group": [
            {
                "arm_group_label": "Atacicept 75 mg", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Atacicept 150 mg", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "This is a multi-center, double-blind, randomized, Phase 2b trial to evaluate the efficacy of\n      atacicept in subjects with systemic lupus erythematosus (SLE)."
        }, 
        "brief_title": "Efficacy and Safety of Atacicept in Systemic Lupus Erythematosus", 
        "completion_date": {
            "#text": "April 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Lupus Erythematosus, Systemic", 
        "condition_browse": {
            "mesh_term": "Lupus Erythematosus, Systemic"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Eligible male and female subjects, aged 18 years or older\n\n          -  Must have at least moderately active SLE, as defined as SLE Disease Activity\n             Index-2000  (SLEDAI-2K) score greater than or equal to [>=] 6 at screening visit\n\n          -  At least 4 of the 11 American college of rheumatology (ACR) classification criteria\n             for SLE (diagnosed >= 6 months prior to the screening visit)\n\n          -  Be seropositive for anti-nuclear antibodies (ANA) and/or anti-double-stranded\n             deoxyribonucleic acid (anti-dsDNA) antibodies\n\n          -  Other protocol defined inclusion criteria could apply\n\n        Exclusion Criteria:\n\n          -  Subjects have demyelinating disorder\n\n          -  Severe central nervous system SLE\n\n          -  Use of cyclophosphamide within 3 months of the screening visit\n\n          -  Urine protein:creatinine ratio (UPCr) >= 2 milligram per milligram (mg/mg) per day\n\n          -  Other protocol defined exclusion criteria could apply"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "279", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 24, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01972568", 
            "org_study_id": "700461-023", 
            "secondary_id": "2013-002773-21"
        }, 
        "intervention": [
            {
                "arm_group_label": "Atacicept 75 mg", 
                "description": "Atacicept 75 mg will be administered as subcutaneous injection once weekly for 24 weeks.", 
                "intervention_name": "Atacicept 75 milligram (mg)", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Atacicept 150 mg", 
                "description": "Atacicept 150 mg will be administered as subcutaneous injection once weekly for 24 weeks.", 
                "intervention_name": "Atacicept 150 mg", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "Placebo matched to atacicept will be administered as subcutaneous injection once weekly for 24 weeks.", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Atacicept 75 and 150 mg", 
            "Placebo"
        ], 
        "lastchanged_date": "December 3, 2013", 
        "location": [
            {
                "contact": {
                    "last_name": "for US Recruiting Sites", 
                    "phone": "888-275-7376"
                }, 
                "facility": {
                    "address": {
                        "city": "Rockland", 
                        "country": "United States", 
                        "state": "Massachusetts"
                    }, 
                    "name": "Please Contact U.S. Medical Information Located in"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "service@merckgroup.com", 
                    "last_name": "for EU Recruiting Sites", 
                    "phone": "+49 6151 72 5200"
                }, 
                "facility": {
                    "address": {
                        "city": "Darmstadt", 
                        "country": "Germany"
                    }, 
                    "name": "Please Contact the Merck KGaA Communication Center Located in"
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "United States", 
                "Germany"
            ]
        }, 
        "number_of_arms": "3", 
        "official_title": "A Phase IIb, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Multidose, 24-Week Study to Evaluate the Efficacy and Safety of Atacicept in Subjects With Systemic Lupus Erythematosus (SLE)", 
        "overall_contact": {
            "last_name": "US Medical Information", 
            "phone": "888-275-7376"
        }, 
        "overall_contact_backup": {
            "email": "service@merckgroup.com", 
            "last_name": "Merck KGaA Communication Center", 
            "phone": "+49 6151 72 5200"
        }, 
        "overall_official": {
            "affiliation": "EMD Serono, Inc., Rockland MA, a subsidiary of Merck KGaA, Darmstadt, Germany", 
            "last_name": "Medical Responsible", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "European Union: European Medicines Agency"
            ]
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "April 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Percentage of subjects with SLE responder index (SRI) response at Week 24 compared to screening", 
            "safety_issue": "No", 
            "time_frame": "Screening and Week 24"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01972568"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Percentage of subjects at Week 24 whose prednisone-equivalent corticosteroid dose has reduced from Screening by >= 25 percent and to a dose of =< 7.5 milligram per day (mg/day), and have no BILAG A or 2B flare in disease activity during Weeks 16 to 24", 
                "safety_issue": "No", 
                "time_frame": "Screening and Week 24"
            }, 
            {
                "measure": "Percentage of subjects in the patient global impression of change (PGIC) categories at Week 24", 
                "safety_issue": "No", 
                "time_frame": "Week 24"
            }, 
            {
                "measure": "Change from screening visit to Week 24 in prednisone-equivalent corticosteroid (CS) daily dose", 
                "safety_issue": "No", 
                "time_frame": "Screening and Week 24"
            }, 
            {
                "measure": "Time to first SRI response during the treatment period", 
                "safety_issue": "No", 
                "time_frame": "24 Weeks"
            }, 
            {
                "measure": "Percentage of subjects responding to treatment according to British Isles Lupus Assessment Group (BILAG)-based Combined Lupus Assessment (BICLA)", 
                "safety_issue": "No", 
                "time_frame": "Week 24"
            }, 
            {
                "measure": "Change from Day 1 in medical outcomes study 36-item short form health survey (SF-36)-physical component summary (PCS) and mental component summary (MCS)", 
                "safety_issue": "No", 
                "time_frame": "Week 24"
            }, 
            {
                "measure": "Number of subjects with adverse events (AEs)", 
                "safety_issue": "Yes", 
                "time_frame": "Screening up to 48 weeks"
            }
        ], 
        "source": "EMD Serono", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "EMD Serono", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "November 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 2013"
    }
}